<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01581840</url>
  </required_header>
  <id_info>
    <org_study_id>FFCD 0904</org_study_id>
    <nct_id>NCT01581840</nct_id>
  </id_info>
  <brief_title>Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus</brief_title>
  <official_title>Phase I-II on Radiochemotherapy Combined With Panitumumab in the Treatment of Localised Epidermoid Carcinoma of the Anus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federation Francophone de Cancerologie Digestive</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment is based on radiochemotherapy for locally advanced tumours. The objective of&#xD;
      treatment is to provide a cure without resorting to abdominoperineal amputation, while&#xD;
      preserving sphincter function.&#xD;
&#xD;
      The prognosis is mainly related to tumour size and lymph node invasion. The large majority of&#xD;
      patients do not show any spread remote from the tumour at the time of diagnosis (2).&#xD;
&#xD;
      Recurrences are mainly of a local/regional nature and require abdominoperineal amputation.&#xD;
      This type of intervention is not always possible or complete, which then gives rise to the&#xD;
      particularly distressing risk of local progression, with survival at 3 years of approximately&#xD;
      30% (3).&#xD;
&#xD;
      It is therefore very important to achieve a complete and permanent tumour response from&#xD;
      initial treatment with radiochemotherapy.&#xD;
&#xD;
      Furthermore, the use of an anti-EGFR antibody in combination with exclusive radiotherapy in&#xD;
      ENT cancer was able to increase recurrence-free survival and overall survival in these&#xD;
      patients. These data are in favour of the use of a combination of chemotherapy and anti-EGFR&#xD;
      antibodies in epidermoid cancer of the anus.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2012</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I = determination the maximum tolerated dose 5FU and panitumumab in combination with radiotherapy and mitomycin, and thereby to deduce the maximum tolerated dose in patient with localised epidermoid carcinoma of the anus</measure>
    <time_frame>9 weeks after the beginning of treatment</time_frame>
    <description>Phase I = determine the dose limiting toxicity of 5FU and panitumumab in combination with radiotherapy and mitomycin, and thereby to deduce the maximum tolerated dose in patient with localised epidermoid carcinoma of the anus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II = Complete response of the tumor rectal examination and morphological exams</measure>
    <time_frame>8 weeks evaluations after the end of the treatment by radiochemotherapy</time_frame>
    <description>phase II = Response criteria: complete desappearance of the tumor upon rectal examination and morphological exams (MRI, endoscopic ultrasonography) and non appearance of secondary lesions, response validated by an independant committee.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase II = Partial response rate, stable disease and progression</measure>
    <time_frame>6 weeks and 17 weeks after the beginning of treatment</time_frame>
    <description>Intermediate objective response rate (complete and partial) at 6 weeks (before the additional radiotherapy). The 80% reduction rate in the largest tumour diameter will also be recorded.&#xD;
Partial response rate, stable disease and progression 8 weeks after the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II = Colostomy-free survival</measure>
    <time_frame>At 3 years after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II = Recurrence-free survival at 3 years</measure>
    <time_frame>At 3 years after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II = Overall survival</measure>
    <time_frame>At 3 years after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II = Quality of life (EORTC QLQ-C30 + Wexner questionnaire)</measure>
    <time_frame>At 3 years after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Epidermoid Carcinoma</condition>
  <condition>Anus</condition>
  <arm_group>
    <arm_group_label>5Fu-mitomycine-panitumumab + radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 FU = 400 or 600 or 80 or 1000 mg depending of phase I results, days 1 to 4 weeks 1, 5 and 8 mitomicyne = 10 mg/m² day 1 week 1 and days 1, weeks 5 and 8 Panitumumab = 3 or 6 mg/kg (depending of phase I results) days 1, weeks: 1, 3, 5, 8 and 10</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>radiochemotherapy</intervention_name>
    <description>Radiotherapy : PTV1 45 Gy 5 weeks PTV2 20 Gy 2 weeks Chemotherapy : 5Fu (400 to 1000 mg/m²) mitomycin : 10 mg/m²</description>
    <arm_group_label>5Fu-mitomycine-panitumumab + radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>3 or 6 mg/kg (according to dose level)</description>
    <arm_group_label>5Fu-mitomycine-panitumumab + radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven epidermoid carcinoma of the anus&#xD;
&#xD;
          -  Locally advanced tumour without metastases&#xD;
&#xD;
          -  Stage T2&gt;3 cm or T3 or T4, irrespective of N&#xD;
&#xD;
          -  Stage N1-N3 irrespective of T stage (T1 to T4)&#xD;
&#xD;
          -  General condition WHO 0-1&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Effective contraception in female and/or male patients having reached sexual maturity&#xD;
             during treatment and up to 6 months after the end of treatment&#xD;
&#xD;
          -  CD4 &gt; 400 / mm3&#xD;
&#xD;
          -  Measureable tumor on at least one of the following exams : MRI, endoscopic&#xD;
             ultrasonography, clinical exam&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of metastases&#xD;
&#xD;
          -  Previous anti-EGFR therapy&#xD;
&#xD;
          -  Stage T1N0 or T2 &lt; 3 cm N0&#xD;
&#xD;
          -  History of pelvic radiotherapy&#xD;
&#xD;
          -  At least one of the following laboratory test results: Neutrophils &lt; 1500 /mm3,&#xD;
             platelets &lt; 100 000 /mm3, Hb &lt; 9 g/dl, leukocytes &lt; 3000/mm3, blood bilirubin &gt; 1.5&#xD;
             times the upper limit of the normal range, transaminase (ASAT and ALAT) &gt; 2.5 times&#xD;
             the upper limit of the normal range, creatinine clearance &lt; 50 mL/min (Cockcroft's&#xD;
             formula Appendix x), Mg2+ &lt; the lower limit of the normal range, Ca2+ &lt; the lower&#xD;
             limit of the normal range&#xD;
&#xD;
          -  Significant coronary artery disease or myocardial infarction in the past year&#xD;
&#xD;
          -  Follow-up not possible due to psychological or geographic reasons&#xD;
&#xD;
          -  History of interstitial pneumonitis or pulmonary fibrosis&#xD;
&#xD;
          -  History of malignant disease in the past five years apart from basocellular skin&#xD;
             carcinoma or in situ cervical carcinoma having received adequate treatment&#xD;
&#xD;
          -  Pregnant or breast-feeding women, women of child-bearing potential not having taken a&#xD;
             pregnancy test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Véronique VENDRELY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Haut-Lévêque - Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pessac - Hôpital Haut Lévêque</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH - Hopitaux civils de Colmar</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'oncologie et de radiothérapie du Parc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH - CHBS - Hôpital du Scorff</name>
      <address>
        <city>Lorient</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Régional du Cancer Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Privée - Plein Ciel</name>
      <address>
        <city>Mougins</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cario - HPCA - Hôpital privé des Côtes D'Armor</name>
      <address>
        <city>Plérin</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH - Annecy Genevois</name>
      <address>
        <city>Pringy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Saint Cloud</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAC - Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Vendrely V, Lemanski C, Gnep K, Barbier E, Hajbi FE, Lledo G, Dahan L, Terrebonne E, Manfredi S, Mirabel X, Mammar V, Cowen D, Lepage C, Aparicio T; for FFCD investigators/Collaborators. Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase I dose-escalation study with panitumumab (FFCD 0904). Radiother Oncol. 2019 Nov;140:84-89. doi: 10.1016/j.radonc.2019.05.018. Epub 2019 Jun 8.</citation>
    <PMID>31185328</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 6, 2012</study_first_submitted>
  <study_first_submitted_qc>April 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2012</study_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anus</keyword>
  <keyword>carcinoma</keyword>
  <keyword>panitumumab</keyword>
  <keyword>mitomycine</keyword>
  <keyword>5Fu</keyword>
  <keyword>radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Anus Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

